Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies

Current Hematologic Malignancy Reports, Journal Year: 2025, Volume and Issue: 20(1)

Published: Jan. 4, 2025

Abstract Purpose of Review Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden cost-effectiveness therapies crucial for clinicians researchers. Recent Findings In this, we review recent approval Bispecific antibodies CAR-T their cost implications, including direct indirect costs. We compare this to current regimens provide comparisons in review. Summary conclude that use more effective such as earlier lines may be cost-effective depending on country model used. Further studies are essential better understand bispecific head-to-head therapy.

Language: Английский

---

Charged substrate treatment enhances T cell mediated cancer immunotherapy

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 12, 2025

Biophysical cues play a crucial role in T cell biology, yet their implications adoptive therapy (ACT) remain largely unknown. Here, we investigate the effect of electrical stimuli on CD8+ cells using charged substrate composed electroactive nanocomposites with tunable surface charge intensities. Electrical enhance persistence and tumor-suppressive efficacy transferred cells, effects dependent charge. Single-cell RNA-sequencing analysis unveils decrease virtual memory (Tvm) an increase proliferative potential (Tpp) which exhibit superior antitumor activity metabolic adaptations relative to those treated uncharged substrate. ATAC-seq profiling demonstrates heightened accessibility at upstream binding sites for EGR1, transcription factor critical Tpp differentiation. Mechanistically, disrupts ionic TCR-lipid interactions, amplifies TCR signaling, activates thereby impeding Tvm polarization during ex vivo culture. Our findings thus highlight importance extracellular shaping fate, offering optimizing ACT therapeutic applications. elusive. Here authors use proliferation anti-tumor function transfer therapy, mechanism amplifying activating EGR1 signaling polarization.

Language: Английский

---

Impacts of ageing on the efficacy of CAR-T cell therapy

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102715 - 102715

Published: March 1, 2025

Language: Английский

---

Review on gene and cell therapies in prostate cancer treatment: prospects and challenges

Journal of Translational Genetics and Genomics, Journal Year: 2025, Volume and Issue: 9(2), P. 62 - 75

Published: March 21, 2025

Gene and cell therapies have emerged as innovative therapeutic strategies, offering a new paradigm in the treatment of prostate cancer. This review explores current state gene therapies, including their mechanisms, applications, challenges faced clinical translation. The article selection was based on 2020 preferred reporting items for systematic reviews meta-analyses (PRISMA). Eighty-four (84) articles (published English between 2018 2024) from standard electronic databases were extracted reviewed. Key approaches such viral vector-mediated delivery, CRISPR-Cas9 editing, suicide genes, cell-based like CAR T therapy, dendritic vaccines that target specific tumor antigens These promise to enhance efficacy with few challenges, off-target effects, limited delivery efficiency, immune-related toxicities associated delivery. Advances cells, nanoparticle-based systems, epigenetic modulation are potential solutions these challenges. Combination involving immunotherapies oncolytic viruses hold synergistic effects. Certain critical regulatory, ethical, accessibility issues must be addressed ensure safe equitable deployment therapies. Continued research innovation streamlined regulatory pathways will crucial realizing full treating Overcoming fears confronting worldwide might facilitate stream personalized medicine oncology.

Language: Английский

---

Screening and mechanistic study of natural compounds that enhance T cell anti-tumor effects post-heat treatment

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 27, 2025

Introduction Following the approval of Chimeric Antigen Receptor T-cell Immunotherapy(CAR-T) in multiple countries, Food and Drug Administration (FDA) approved tumor-infiltrating lymphocytes (TILs) receptor-engineered T cells (TCR-T) treatments this year. The utilization adoptive immunotherapy tumor treatment has become increasingly prominent. Optimizing cytotoxic effects immune under vitro culture conditions represents a current hot research topic domain. Methods In experiment, we conducted heat on Jurkat-derived at 39°C. On basis, utilized nine distinct injectable solutions over 70 monomer components Traditional Chinese Medicine (TCM). Subsequently, co-cultured these treated Jurkat with K562-eGFP cells, co-culture process was monitored real-time using IncuCyte live-cell analysis system. Equally important, combined HiMAP high-throughput transcriptome sequencing, proteomics, metabolomics for in-depth examination. We screened compounds possessing anti-tumor properties thoroughly investigated their mechanisms action. Results Discussion findings indicated that heating augmented effect against malignant tumors, optimal achieved when were exposed to 39°C duration 24 hours(48% increase cell proliferation rate compared 37°C treatment). By triggering generation shock proteins facilitating mitochondrial energy supply, amplified functions cells. analyzing data, identified 3 more than 20 effective monomers capable further enhancing tumor-killing ability High-throughput transcriptomics studies disclosed combination thermotherapy TCM promoted proliferation, activation, thereby activating Regulation mitotic cycle exert effects. integration transcriptomic proteomic data demonstrated Shengmai Injection significantly enhances by down-regulating Apoptosis signaling pathways.

Language: Английский

---